Title 21-FOOD AND DRUGS is composed of nine volumes. The parts in these volumes are arranged in the following order: Parts 1-99, 100-169, 170-199, 200-299, 300-499, 500-599, 600-799, 800-1299 and 1300-end. The first eight volumes, containing parts 1-1299, comprise Chapter I-Food and Drug Administration, Department of Health and Human Services. The ninth volume, containing part 1300 to end, includes Chapter II-Drug Enforcement Administration, Department of Justice, and Chapter III-Office of National Drug Control Policy. The contents of these volumes represent all current regulations codified under this title of the CFR as of April 1, 2000. Redesignation tables for Chapter I-Food and Drug Administration appear in the Finding Aids section for the volumes containing parts 170-199 and 500-599. For this volume, Lisa N. Morris was Chief Editor. The Code of Federal Regulations publication program is under the direction of Frances D. McDonald, assisted by Alomha S. Morris. know... if any changes have been made to the Code of Federal Regulations or what documents have been published in the Federal Register without reading the Federal Register every day? If so, you may wish to subscribe to the LSA (List of CFR Sections Affected), the Federal Register Index, or both. Order Processing Code: *5421 Superintendent of Documents Subscription Order Form YES, send me the following indicated subscriptions for one year: Drugs (This book contains parts 1 to 99) Part CHAPTER I —Food and Drug Administration, Department of 1 CROSS REFERENCES: Food Safety and Inspection Service, Department of Agriculture: 9 CFR chapter III. Federal Trade Commission: See Commercial Practices, 16 CFR chapter I. U.S. Customs Service, Department of the Treasury: See Customs Duties, 19 CFR chapter I. Internal Revenue Service, Department of the Treasury: See Internal Revenue, 26 CFR chapter I. Bureau of Alcohol, Tobacco, and Firearms, Department of the Treasury: See Alcohol, Tobacco Products and Firearms, 27 CFR chapter I. Electronic records; electronic signatures ..... Public hearing before a public board of inquiry Regulatory hearing before the Food and Drug Ad- 113 117 134 139 165 168 Civil money penalties hearings 173 20 Standards of conduct and conflicts of interest 186 ....... 188 Protection of privacy 217 25 Environmental impact considerations 233 Mutual recognition of pharmaceutical good manu- Financial disclosure by clinical investigators 58 Good laboratory practice for nonclinical labora tory studies 297 60 Patent term restoration 311 |